Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2026)

Royalty Pharma has reported Cash from Financing Activities for 8 years, with the latest figure at -$272.7 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 71.03% year-over-year to -$272.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$517.3 million (down 40.52% YoY) and the FY2025 annual result came in at -$1.2 billion, down 428.39% from the prior year.
• Cash from Financing Activities rose to -$272.7 million in Q1 2026 per RPRX's latest filing, from -$299.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.2 billion in Q2 2024 and troughed at -$1.4 billion in Q3 2023.
• A 5-year average of -$246.5 million and a median of -$258.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 490.86% in 2023, then jumped 433.32% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$265.6 million in 2022, then rose by 12.67% to -$231.9 million in 2023, then decreased by 11.24% to -$258.0 million in 2024, then fell by 16.14% to -$299.6 million in 2025, then rose by 8.99% to -$272.7 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$272.7 million, -$299.6 million, and $562.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.